Table 5 Features of new-onset OMG and GMG patients following COVID-19 outbreak
From: The characteristics of new-onset myasthenia gravis after COVID-19 outbreak: a cross-sectional study
Variables | OMG (n = 107) | GMG (n = 87) | P value |
|---|---|---|---|
Gender, female, n (%) | 51 (47.66) | 54 (62.07) | 0.045* |
Vaccination, ≥ 1, n (%) | 94 (87.85) | 77 (88.51) | 0.888 |
Infection rate, n (%) | 99 (92.52) | 86 (98.85) | 0.082 |
MG duration (w), median (IQR) | 14 (5, 27) | 16 (7, 36) | 0.065 |
Age at onset (y), median (IQR) | 37 (18, 54) | 43 (35, 55) | 0.013* |
Abnormal thymus (missed 1), n (%) | 36 (33.96) | 33 (37.93) | 0.535 |
Thymic pathology (13 = OMG and 14 = GMG), n (%) |  |  | 0.016* |
 Thymic hyperplasia | 5 (38.46) | 0 (0) |  |
 Thymoma | 8 (61.54) | 14 (100.00) |  |
RNS + (missed 13), n (%) | 40 (39.60) | 48 (60.00) | 0.013* |
Antibody status (missed 3) |  |  |  < 0.00*1 |
 AChRab +, n (%) | 78 (74.28) | 59 (68.60) | 0.386 |
 MuSKab +, n (%) | 0 (0) | 16 (18.60) |  < 0.001* |
LRP4ab + or RyR ab + or Titin ab +, n (%) | 3 (2.86) | 1 (1.16) | 0.760 |
Seronegative, n (%) | 24 (22.86) | 10 (11.63) | 0.044* |
MG treatment | Â | Â | Â |
 Pyridostigmine, n (%) | 104 (97.20) | 83 (95.40) | 0.505 |
 Prednisolone, n (%) | 60 (56.07) | 76 (87.36) |  < 0.001* |
 Immunosuppressants, n (%) | 11 (10.28) | 36 (41.38) |  < 0.001* |
 Tacrolimus, n (%) | 8 (7.48) | 23 (26.44) |  < 0.001* |
 MMF, n (%) | 2 (1.87) | 8 (9.20) | 0.022* |
 AZA, n (%) | 1 (0.93) | 5 (5.75) | 0.131 |
Baseline MG-ADL, median (IQR) | 3 (3, 6) | 5 (3, 6) | 0.027* |
Baseline QMGS, median (IQR) | 5 (4, 7) | 9 (6, 14) |  < 0.001* |